drugset / Trial / NCT05103826
A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The study is being conducted to assess the safety 、tolerability 、 pharmacokinetics and efficacy of SHR6390 combined with famitinib in the treatment of ER + / HER2- advanced breast cancer.
Timeline
- Start
- 2021-10-25
- Primary completion
- 2023-06-15
- Completion
- 2023-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalpiciclib | Small molecule | — | Oral |
| Subject | Famitinib | Small molecule | — | Oral |